BiVictriX develops next-generation antibody-drug conjugates (ADCs) using its proprietary Bi-Cygni® platform, which enhances the visibility of cancer cells for precise targeting. This approach addresses the challenge of effectively treating aggressive cancers by allowing for higher, more effective doses of therapy while minimizing harm to healthy cells.
Funding
Funding not disclosed
Founders
Product
Problem
Many aggressive cancers are difficult to treat because cancer cells effectively "hide" among healthy cells, making them difficult to target with precision therapies. Existing cancer treatments often lack the selectivity needed to deliver effective doses without harming healthy tissues.
Solution
BiVictriX is developing next-generation antibody-drug conjugates (ADCs) with improved cancer selectivity using its proprietary Bi-Cygni® platform. The Bi-Cygni® approach enhances the visibility of cancer cells, enabling more precise targeting and delivery of potent chemotherapy warheads. By selectively unmasking cancer cells, BiVictriX's ADCs aim to deliver higher, more effective doses of therapy while minimizing off-target effects and improving patient outcomes. This approach seeks to revolutionize cancer therapy by providing longer-term, durable responses for patients suffering from difficult-to-treat cancers.
Target Audience
The primary target audience includes clinicians and patients seeking more effective and less toxic treatments for aggressive cancers.
Features
- Bi-Cygni® platform for enhanced cancer cell visibility and selective targeting
- Development of next-generation antibody-drug conjugates (ADCs)
- Improved cancer selectivity to minimize harm to healthy cells
- Potential for higher, more effective doses of therapy